Loading...

Pau Castel Morales, PhD

TitlePostdoctoral Scholar
SchoolUCSF School of Medicine
DepartmentHDF Comprehensive Cancer Ctr
Address1450 Third St
San Francisco CA 94158
Phone415-502-1710
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN, Scaltriti M, Leslie CS, Armstrong SA, Baselga J. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science. 2017 Mar 24; 355(6331):1324-1330. PMID: 28336670.
      View in: PubMed
    2. Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, Meier P, Gris-Oliver A, Cheang MC, Perdrix-Rosell A, Shafat M, Noël E, Patel N, McEachern K, Scaltriti M, Castel P, Noor F, Buus R, Mathew S, Watkins J, Serra V, Marra P, Grigoriadis A, Tutt AN. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat Med. 2016 Oct 24. PMID: 27775704.
      View in: PubMed
    3. Castel P, Scaltriti M. The emerging role of serum/glucocorticoid-regulated kinases in cancer. Cell Cycle. 2016 Sep 16; 1-2. PMID: 27636373.
      View in: PubMed
    4. Le X, Antony R, Razavi P, Treacy DJ, Luo F, Ghandi M, Castel P, Scaltriti M, Baselga J, Garraway LA. Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. Cancer Discov. 2016 Oct; 6(10):1134-1147. PMID: 27604488.
      View in: PubMed
    5. Bago R, Sommer E, Castel P, Crafter C, Bailey FP, Shpiro N, Baselga J, Cross D, Eyers PA, Alessi DR. The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth. EMBO J. 2016 Sep 1; 35(17):1902-22. PMID: 27481935; PMCID: PMC5007552 [Available on 09/01/17].
      View in: PubMed, PubMed Central
    6. Castel P, Ellis H, Bago R, Toska E, Razavi P, Carmona FJ, Kannan S, Verma CS, Dickler M, Chandarlapaty S, Brogi E, Alessi DR, Baselga J, Scaltriti M. PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Ka Inhibition. Cancer Cell. 2016 Aug 8; 30(2):229-42. PMID: 27451907; PMCID: PMC4982440.
      View in: PubMed, PubMed Central
    7. Soler A, Figueiredo AM, Castel P, Martin L, Monelli E, Angulo-Urarte A, Mila-Guasch M, Viñals F, Baselga J, Casanovas O, Graupera M. Therapeutic benefit of selective inhibition of p110a PI3-kinase in pancreatic neuroendocrine tumors. Clin Cancer Res. 2016 May 25. PMID: 27225693.
      View in: PubMed
    8. Castel P, Carmona FJ, Grego-Bessa J, Berger MF, Viale A, Anderson KV, Bague S, Scaltriti M, Antonescu CR, Baselga E, Baselga J. Somatic PIK3CA mutations as a driver of sporadic venous malformations. Sci Transl Med. 2016 Mar 30; 8(332):332ra42. PMID: 27030594; PMCID: PMC4962922.
      View in: PubMed, PubMed Central
    9. Grego-Bessa J, Bloomekatz J, Castel P, Omelchenko T, Baselga J, Anderson KV. The tumor suppressor PTEN and the PDK1 kinase regulate formation of the columnar neural epithelium. Elife. 2016 Jan 26; 5:e12034. PMID: 26809587; PMCID: PMC4739759.
      View in: PubMed, PubMed Central
    10. Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, Perez-Garcia J, Galvan P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S, Scaltriti M, Baselga J. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med. 2015 Apr 15; 7(283):283ra51. PMID: 25877889; PMCID: PMC4433148.
      View in: PubMed, PubMed Central
    11. Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, Ebbesen SH, Ainscough BJ, Ramu A, Iyer G, Shah RH, Huynh T, Mino-Kenudson M, Sgroi D, Isakoff S, Thabet A, Elamine L, Solit DB, Lowe SW, Quadt C, Peters M, Derti A, Schegel R, Huang A, Mardis ER, Berger MF, Baselga J, Scaltriti M. Convergent loss of PTEN leads to clinical resistance to a PI(3)Ka inhibitor. Nature. 2015 Feb 12; 518(7538):240-4. PMID: 25409150; PMCID: PMC4326538.
      View in: PubMed, PubMed Central
    12. Castel P, Toska E, Zumsteg ZS, Carmona FJ, Elkabets M, Bosch A, Scaltriti M. Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment. Mol Cell Oncol. 2014 Jul-Sep; 1(3):e963447. PMID: 27308344; PMCID: PMC4904898.
      View in: PubMed, PubMed Central
    13. Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Bosch A, Juric D, Hazra S, Singh S, Kim P, Bergamaschi A, Maheswaran S, Ng T, Penault-Llorca F, Lewis JS, Carey LA, Perou CM, Baselga J, Scaltriti M. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal. 2014 Mar 25; 7(318):ra29. PMID: 24667376; PMCID: PMC4283215.
      View in: PubMed, PubMed Central
    Pau's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (37) concept(s)
    _
    Related Authors
    People who share related concepts with this person.
    See all (60) people
    _
    Back to TOP